Pil Højgaard1, Louise Klokker2, Ana-Maria Orbai3, Kim Holmsted2, Else M Bartels2, Ying Ying Leung4, Niti Goel5, Maarten de Wit6, Dafna D Gladman7, Philip Mease8, Lene Dreyer1, Lars E Kristensen2, Oliver FitzGerald9, William Tillett10, Laure Gossec11, Philip Helliwell12, Vibeke Strand13, Alexis Ogdie14, Caroline B Terwee15, Robin Christensen16. 1. The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark; Department of Rheumatology, Rigshospitalet, Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark. 2. The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark. 3. Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD. 4. Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Rd, the Academia, S169856, Singapore. 5. Division of Rheumatology, Duke University School of Medicine, Advisory Services, QuintilesIMS, Durham, NC. 6. VU University Amsterdam, Department of Medical Humanities, Amsterdam, the Netherlands. 7. Division of Rheumatology and Krembil Research Institute, University Health Network, Toronto Western Hospital, 399 Bathurst St, 1E-410B, Toronto, Ontario, Canada M5T 2S8. 8. Division of Rheumatology Clinical Research, Swedish Medical Center, Seattle, WA. 9. Department of Rheumatology, St Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Ireland. 10. Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Pharmacy and Pharmacology, University of Bath, Bath, UK. 11. Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitie-Salpétrière Hospital, AP-HP, Rheumatology Department, 47-83 Bd de l'Hopital, Paris 75013, France. 12. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Harehills Lane, Leeds LS7 4SA, UK. 13. Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA. 14. Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 15. VU University Medical Center, Department of Epidemiology and Biostatistics and Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. 16. The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, DK-2000, Copenhagen, Denmark. Electronic address: Robin.christensen@regionh.dk.
Abstract
BACKGROUND: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. OBJECTIVES: To synthesize the evidence on measurement properties of patient reported outcome measures (PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) as described by the OMERACT Filter 2.0. METHODS: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1, 2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA. Two independent reviewers rated the quality of studies using the COnsensus based standards for the Selection of health Measurement INstruments (COSMIN) checklist, and performed a qualitative evidence synthesis. RESULTS: Fifty-five studies were included in the systematic review. Forty-four instruments and a total of 89 scales were analyzed. PROMs measuring COS domains with at least fair quality evidence for good validity and reliability (and no evidence for poor properties) included the Stockerau Activity Score for PsA (German), Psoriasis Symptom Inventory, visual analogue scale for Patient Global, 36 Item Short Form Health Survey Physical Function subscale, Health Assessment Questionnaire Disability Index, Bath Ankylosing Spondylitis Functional Index, PsA Impact of Disease questionnaire, PsA Quality of Life questionnaire, VITACORA-19, Functional Assessment of Chronic Illness Therapy Fatigue scale and Social Role Participation Questionnaire. CONCLUSIONS: At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight mandatory domains of the PsA COS.
BACKGROUND: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. OBJECTIVES: To synthesize the evidence on measurement properties of patient reported outcome measures (PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) as described by the OMERACT Filter 2.0. METHODS: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1, 2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA. Two independent reviewers rated the quality of studies using the COnsensus based standards for the Selection of health Measurement INstruments (COSMIN) checklist, and performed a qualitative evidence synthesis. RESULTS: Fifty-five studies were included in the systematic review. Forty-four instruments and a total of 89 scales were analyzed. PROMs measuring COS domains with at least fair quality evidence for good validity and reliability (and no evidence for poor properties) included the Stockerau Activity Score for PsA (German), Psoriasis Symptom Inventory, visual analogue scale for Patient Global, 36 Item Short Form Health Survey Physical Function subscale, Health Assessment Questionnaire Disability Index, Bath Ankylosing Spondylitis Functional Index, PsA Impact of Disease questionnaire, PsA Quality of Life questionnaire, VITACORA-19, Functional Assessment of Chronic Illness Therapy Fatigue scale and Social Role Participation Questionnaire. CONCLUSIONS: At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight mandatory domains of the PsA COS.
Authors: Ana-Maria Orbai; Richard Holland; Ying Ying Leung; William Tillett; Niti Goel; Robin Christensen; Neil McHugh; Laure Gossec; Maarten de Wit; Pil Højgaard; Laura C Coates; Philip J Mease; Julie Birt; Lara Fallon; Oliver FitzGerald; Alexis Ogdie; Beverly Shea; Vibeke Strand; Kristina Callis Duffin; Peter Tugwell; Dorcas Beaton; Dafna D Gladman Journal: J Rheumatol Date: 2018-12-15 Impact factor: 4.666
Authors: Ana-Maria Orbai; Laura C Coates; Atul Deodhar; Philip S Helliwell; Christopher T Ritchlin; Evan Leibowitz; Alexa P Kollmeier; Elizabeth C Hsia; Xie L Xu; Shihong Sheng; Yusang Jiang; Yan Liu; Chenglong Han Journal: Patient Date: 2022-06-30 Impact factor: 3.481
Authors: Ying Ying Leung; Ana-Maria Orbai; Alexis Ogdie; Pil Hojgaard; Richard Holland; Niti Goel; Jeffrey Chau; Laura C Coates; Vibeke Strand; Dafna D Gladman; Philip J Mease; Robin Christensen; William Tillett Journal: J Rheumatol Date: 2020-02-01 Impact factor: 5.346
Authors: Ying Ying Leung; William Tillett; Pil Hojgaard; Ana-Maria Orbai; Richard Holland; Ashish J Mathew; Niti Goel; Jeffrey Chau; Christine A Lindsay; Alexis Ogdie; Laura C Coates; Robin Christensen; Philip J Mease; Vibeke Strand; Dafna D Gladman Journal: J Rheumatol Date: 2021-04-15 Impact factor: 5.346
Authors: Ying Ying Leung; Ana-Maria Orbai; Maarten de Wit; Andra Balanescu; Emmanuelle Dernis; Martin Soubrier; Lihi Eder; Josef S Smolen; Laura C Coates; Laure Gossec Journal: Arthritis Care Res (Hoboken) Date: 2021-03-13 Impact factor: 4.794